Jupiter Endovascular bets catheter control unlocks PE therapy: SPIRARE pivotal trial

A Menlo Park medtech startup selling the Vertex Pulmonary Embolectomy System, a catheter platform whose TFX fixation mechanism stabilizes itself inside blood vessels for clot-removal procedures.

That catheter control is why endovascular therapy is underused — flex to reach a target, lock rigid via saline, and PE treatment becomes possible.

Seeded with $21M carved out of Neptune Medical's $97M Series D in 2024; oversubscribed Series B over $40M closed October 2025

The TFX concept was developed inside Neptune Medical starting in 2020. In July 2024 Neptune spun the program out as Jupiter Endovascular, allocating $21 million of its $97 million Series D to the new company, with Sonder Capital as a major contributor. Carl J. St. Bernard took over as CEO the same month, and Jupiter targeted acute, intermediate-risk pulmonary embolism as its first indication — a disease where one in three patients gets incomplete clot removal today.

Jupiter ran SPIRARE I (NCT06571760), a 10-patient first-in-human study at two European sites, and on September 12, 2025 the FDA cleared the Vertex catheter via 510(k) for insertion of endovascular devices. At TCT 2025 on October 26, results showed no major adverse events within 48 hours, a 32% drop in mean pulmonary artery pressure, and a 71% improvement in dyspnea score at 48 hours. Days earlier, Jupiter announced an oversubscribed Series B past its $40M target, led by Sonder Capital, to fund SPIRARE II — a pivotal trial enrolling up to 145 patients at up to 25 U.S. and European sites (NCT06576427).

Live and enrolling in its pivotal trial: SPIRARE II is recruiting as of October 2025, with proceeds earmarked for completing the trial and preparing for commercialization.

Attacking catheter control, rather than building another thrombectomy device, let Jupiter target every endovascular procedure while starting with the highest unmet need, PE.

The $21M carve-out from Neptune's Series D gave the spinout a funded, dedicated team and technology with years of animal testing behind it.

FDA 510(k) clearance of the delivery catheter de-risked the platform before the pivotal trial, and positive FIH data arrived just before the Series B close.

A medtech startup can differentiate on delivery rather than the treatment itself: fixing catheter control opened a PE pathway existing devices couldn't safely access.

As of October 26, 2025, Jupiter Endovascular holds FDA 510(k) clearance for the Vertex catheter, has reported positive first-in-human results for its PE system at TCT 2025, and is enrolling SPIRARE II, its 145-patient pivotal trial across up to 25 U.S. and European sites. The oversubscribed Series B past $40M — led by Sonder Capital with Senvest Management, LB Investment, and a strategic corporate investor — is funding the pivotal study and commercialization preparation.